Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Bolnica s primarno razsejanim karcinomom danke z zasevki v jetrih
Authors:ID Boc, Marko (Author)
ID Reberšek, Martina (Author)
ID Hlebanja, Zvezdana (Author)
ID Boc, Nina (Author)
ID Ocvirk, Janja (Author)
Files:.pdf PDF - Presentation file, download (331,30 KB)
MD5: CC5AF3CBF1CDDB55B79F1679E96EF7A0
PID: 20.500.12556/dirros/ec9624b2-05d9-45b9-b3ac-352910da5d8e
 
Language:Slovenian
Typology:1.08 - Published Scientific Conference Contribution
Organization:Logo OI - Institute of Oncology
Abstract:Rak debelega črevesa in danke (RDČD) je najpogostejši rak v Sloveniji. Po podatkih Registra raka Slovenije za leto 2008 je v Sloveniji zbolelo 1.450 ljudi(1). Z naraščajočo incidenco narašča tudi umrljivost bolnikov, saj bolezen pri polovici bolnikov še vedno ugotovimo v napredovali obliki. Razsejana bolezen je neozdravljiva bolezen, sta se pa prognoza in preživetje teh bolnikov močno izboljšala, saj zadnjih deset let z uporabo novih zdravil, to je kombinacijo citostatikov (kapecitabin, irinotekan, oksaliplatin) in tarčnih zdravil (cetuksimab, bevacizumab, panitumumab), dosegamo srednja preživetja, ki so daljša od 30 mesecev(2). Kadar kombiniramo sistemsko in kirurško zdravljenje pri bolnikih s samo jetrnimi zasevki, še posebej, če gre za solitarne zasevke, pa 5-letno preživetje lahko presega 50 %. V tem prispevku opisujemo primer bolnice s primarno razsejanim karcinomom danke z zasevki v jetrih, kjer smo v okviru multidisciplinarnega pristopa, s kombinacijo sistemske terapije in večkratne operacije jetrnih zasevkov ter tudi drugimi terapevtskimi pristopi dosegli preživetje, daljše od 50 mesecev.
Keywords:karcinom danke, razsejeni rak, rak danke, zasevki
Publication status:Published
Publication version:Version of Record
Year of publishing:2013
Number of pages:str. 59-62, 77
Numbering:Letn. 17, št. 1
PID:20.500.12556/DiRROS-9131 New window
UDC:616.35-006
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-JVYAT9AJ
COBISS.SI-ID:1555835 New window
Copyright:by Authors
Publication date in DiRROS:31.08.2018
Views:3807
Downloads:742
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Šola tumorjev prebavil, Ljubljana, 30. 11. 2012
Publisher:Onkološki inštitut
COBISS.SI-ID:1553275 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:A patient with primary metastatic rectal carcinoma with metastases in the liver - a case study
Abstract:Colorectal cancer (CC) is the most common cancer in Slovenia. According to the Cancer Registry of the Republic of Slovenia, a total of 1,450 people were diagnosed with colorectal cancer in Slovenia in 2008(1). The increasing incidence also means increasing morbidity, as in half of the patients, the disease is diagnosed when already at an advanced stage. Metastatic disease is incurable, but the prognosis and the survival of these patients have improved considerably, as in the last decade, with the use of new drugs, namely a combination of cytostatics (capecitabine, irinotecan, oxaliplatin) and target drugs (cetuximab, bevacizumab, panitumumab) we have achieved a median survival of more than 30 months(2). When combining systemic and surgical treatment in patients with liver metastases, in particular if these are solitary metastases, the 5-year survival can exceed 50%. In this paper, we present a case of a patient with primary metastatic rectal carcinoma with metastases in the liver. Within the framework of a multidisciplinary approach with a combination of systemic therapy and multiple surgeries of liver metastases, and using also other therapeutic approaches, we have achieved a survival of more than 50 months.


Archive

niGradiv

Back